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gic system during high-sodium diet. Magnesium supplementa-Dietary potassium and magnesium supplementation in cyclospo-
tion, alone and in combination with potassium, protected againstrine-induced hypertension and nephrotoxicity.
the development of renal dopaminergic deficiency in CsA-treatedBackground. Cyclosporine A (CsA)-induced hypertension
SHRs on high-sodium diet. Magnesium supplementation in-and nephrotoxicity are aggravated by high sodium intake. Ac-
creased plasma-free ionized magnesium (iMg) and bone mag-cumulating evidence suggests that potassium and magnesium
supplementation could protect against the detrimental effects nesium by 50 and 16%, respectively.
of dietary salt. In the present study, we tested the hypothesis Conclusions. Our findings indicate that both potassium and
of whether concurrent supplementation with potassium and magnesium supplementations showed beneficial effects against
magnesium could protect against the development of CsA- CsA-induced hypertension and nephrotoxicity. The protective
induced hypertension and nephrotoxicity more effectively than effect of magnesium clearly exceeded that of potassium. The
supplementation with one mineral alone. greatest protection against CsA toxicity was achieved when
Methods. Eight-week-old spontaneously hypertensive rats potassium and magnesium were combined. We also provide
(SHRs) were divided into four groups (N 5 10 in each group): evidence that the development of CsA-induced glomerular,
(1) CsA group (5 mg/kg subcutaneously) receiving high-sodium tubular, and vascular lesions are associated with renal dopamin-
diet (Na 2.6%, K 0.8%, Mg 0.2% wt/wt); (2) CsA group receiv- ergic deficiency.
ing a high-sodium, high-potassium diet (Na 2.6%, K 2.4%, Mg
0.2%); (3) CsA group receiving high-sodium, high-magnesium
diet (Na 2.6%, K 0.8%, Mg 0.6%); and (4) CsA group receiving
Potassium and magnesium deficiency has been impli-high-sodium, high-potassium, high-magnesium diet (Na 2.6%,
K 2.4%, Mg 0.6%). cated in the pathogenesis of arterial hypertension and
Results. CsA induced severe hypertension and deteriorated hypertension-related end-organ damage [1–5]. Further-
renal functions in SHRs on high-sodium diet. Histologically, more, there is accumulating evidence to suggest thatthe kidneys showed severe thickening of the media of the
increased intakes of potassium and magnesium produceafferent artery with fibrinoid necrosis. Potassium supplementa-
tion lowered blood pressure (198 6 5 vs. 212 6 2 mm Hg, P , antihypertensive and other cardioprotective effects [1–7].
0.05) and partially prevented the development of proteinuria Potassium supplementation has been shown to decrease
(225%, P , 0.05). Magnesium supplementation decreased blood pressure dose dependently [7], and it could protect
blood pressure to the same extent but improved renal functions
against the development of stroke even by a blood pres-more effectively than potassium. The greatest protection against
sure-independent mechanism [8, 9]. The beneficial ef-CsA toxicity was achieved when dietary potassium and magne-
sium supplementations were combined. Urinary N-acetyl-b-d- fects of potassium supplementation appear to be en-
glucosaminidase (NAG) excretion, a marker for renal proximal hanced during high-sodium intake and are closely related
tubular damage, increased progressively in CsA-treated SHRs to potassium-induced natriuresis [10–12]. Magnesium in-on the high-sodium diet. Neither potassium nor magnesium in-
fusions, even when given at physiological concentrations,fluenced urinary NAG excretion. We also estimated the activity
of the renal dopaminergic system by measuring 24-hour urinary produce vasodilation of systemic vasculature and coro-
dopamine excretion rates. CsA suppressed the renal dopaminer- nary arteries [13–16]. However, data on the antihyper-
tensive action of oral magnesium supplementation are
still inconsistent [17]. Previous studies suggest that mag-Key words: nephrotoxicity, salt ingestion, renal proximal tubule dam-
age, dopaminergic system, arterial hypertension, end-organ damage. nesium might protect myocardial cells against ischemia-
induced calcium influx by blocking the L-type calcium
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mineral alone [20]. We have shown previously that simul- high-potassium diet (Na 2.6%, K 2.4%, Mg 0.2%); (3)
CsA group receiving a high-sodium, high-magnesiumtaneous potassium and magnesium supplementation pre-
vented the development of salt-induced hypertension diet (Na 2.6%, K 0.8%, Mg 0.6%); and (4) CsA group
receiving high-sodium, high-potassium, high-magnesiumand cardiac hypertrophy in spontaneously hypertensive
rats (SHRs) and that it also markedly improved the ther- diet (Na 2.6%, K 2.4%, Mg 0.6%). The diets were pro-
duced by adding NaCl, KCl, and MgCl2 (Merck, Darm-apeutic effects of several antihypertensive agents [21–25].
Cyclosporine A (CsA) is one of the most important stadt, Germany) to commercially available low-sodium
control chow (R36, Finnewos Aqua, Helsinki, Finland).immunosuppressive agents used for the management of
organ transplantation and autoimmune diseases. Unfor- CsA (Sandimmunt infusion concentrate 50 mg/mL; San-
doz Ltd., Basel, Switzerland) was diluted in a lipid solu-tunately, CsA treatment is often limited by drug-induced
adverse effects like hypertension and nephrotoxicity tion (Intralipidt; Kabi Pharmacia, Stockholm, Sweden)
to produce a 2.5 mg/mL solution, which was administered[26, 27]. CsA-induced hypertension has been shown to
be dependent on the level of dietary salt [28]. We have once a day subcutaneously at a daily dose of 5 mg/kg as
in our previous studies [29, 30].recently shown that high sodium intake aggravates CsA-
induced hypertension and deterioration of kidney func- Protocol 2. In an additional experiment, we investi-
gated the cardiovascular effects of CsA (5 mg/kg subcuta-tions in SHRs [29], and that both magnesium deficiency
as well as increased renin-angiotensin system activity were neously) and high-sodium diet, alone and in combina-
tion, in normotensive WKY rats. In the beginning ofinvolved in the pathogenesis of CsA toxicity [29, 30]. Fur-
thermore, Markell et al were the first to demonstrate a the study, the blood pressure- and body weight-matched
WKY rats were divided into four groups (N 5 5 to 6 inclear association with low plasma ionized magnesium con-
centration, hypertension, hypercholesterolemia, and neph- each group) to receive CsA and different diets for eight
weeks: (1) control group receiving a low-sodium diet;rotoxicity in CsA-treated renal transplant recipients [31].
In the present study, we tested the hypothesis of whether (2) CsA group receiving a low-sodium diet; (3) high-
sodium diet group; and (4) CsA group receiving a high-concurrent supplementation with potassium and magne-
sium could protect against the development of CsA- sodium diet.
induced hypertension and nephrotoxicity more effec-
Measurement of systolic blood pressure and heart ratetively than supplementation with one mineral alone. We
showed that magnesium protects against CsA toxicity Systolic blood pressure and heart rate (HR) were mea-
sured every second week using a tail-cuff blood pressuremore effectively than potassium. The greatest protection
was achieved when potassium and magnesium were com- analyzer (Apollo-2AB, Blood Pressure Analyzer, Model
179-2AB; IITC Life Science, Woodland Hills, CA, USA)bined. The present study also provides evidence that
CsA-induced hypertension and nephrotoxicity are asso- as described previously [29].
ciated with suppressed renal dopaminergic system.
Metabolic studies and sample preparation
At the age of 14 weeks, the rats were housed individu-
METHODS
ally in metabolic cages where they had free access to tap
Experimental animals, diets, and treatment protocols water and chow. Food intake was recorded, and urine
was collected over two consecutive 24-hour periods. TheForty eight-week-old male SHRs (body weight 175 6
5 g) and 22 eight-week-old Wistar-Kyoto (WKY) rats consumption of chow and tap water was measured by
weighing the chow and water bottles, respectively. Urine(body weight 151 6 4 g; Harlan Sprague Dawley, India-
napolis, IN, USA) were used. The procedures and proto- volumes were measured and samples stored at 2808C
until the biochemical determinations were performed.cols of the study were in accord with our institutional
guidelines and were approved by the Animal Experi- At the end of the experimental period, the animals were
decapitated 24 hours after the last CsA administration.mentation Committee of the Institute of Biomedicine
(University of Helsinki, Helsinki, Finland). The rats were Blood samples for plasma renin activity (PRA) and for
the whole-blood CsA determination were taken intohoused four to five animals per cage in a standard experi-
mental animal laboratory (illuminated from 6.30 a.m. chilled tubes in ice with ethylenediaminetetraacetic acid
(4.5 mmol/L) as anticoagulant. Blood samples for serumuntil 6.30 p.m., temperature 22 6 18C), and they had
free access to tap water and chow during the experiment. creatinine, aldosterone, and cholesterol determinations
were taken into glass tubes without an anticoagulant.Protocol 1. At the beginning of the study, the blood
pressure- and body weight-matched SHRs were divided Blood samples for plasma-free ionized magnesium (iMg)
determination were collected into special calcium-titratedinto four groups (N 5 10) to receive CsA and different
diets for six weeks: (1) CsA group (5 mg/kg subcutane- lithium heparin tubes containing 25 IU/mL blood IL
teste balanced heparin (BC1 Electrolytes Instrumenta-ously) receiving a high-sodium diet (Na 2.6%, K 0.8%,
Mg 0.2% wt/wt); (2) CsA group receiving a high-sodium, tion Laboratory; IL Company, Lexington, MA, USA).
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The iMg samples were stored on ice until assayed within Ionized magnesium was measured directly with selective
electrode for magnesium and calcium from an undiluted4 6 1 hours. The heart was excised; the great vessels,
atria, and free wall of the right ventricle were dissected, sample (Microlyte 6 KONE Instruments, Espoo, Fin-
land) according to the protocol of the manufacturer. Theand the left ventricle mass was measured. The ratio of
the left ventricular wet weight to body weight was calcu- activity of urinary N-acetyl-b-d-glucosaminidase (NAG)
was determined by using 3-cresolsulfonphtalein-N-ace-lated as an index of left ventricular hypertrophy (LVH).
The kidneys were washed with ice-cold saline and tyl-b-glucosamine as the substrate [33]. The method was
adapted to a Cobas Fara II random access analyzer (F.weighed. Tissue samples of heart and kidney were taken
for CsA determinations, and samples of femur for elec- Hoffman-La Roche, Basel, Switzerland). Kinetic follow-
up of the reaction was used instead of determining endtrolyte determinations.
point absorbance. Total protein concentration of urine
Tissue preparation for morphology was determined by the method of Lowry et al [34] after
precipitation with 10% trichloroacetic acid. Urine andFor conventional morphology, the kidneys were re-
moved, cut sagittally, and fixed with 4% buffered para- serum creatinine were analyzed with an enzymatic ana-
lyzer (Kone Specific; Kone Co., Espoo, Finland). Elec-formaldehyde at room temperature. Tissues were dehy-
drated in gradual alcohols and embedded in paraffin. trolytes were determined using a Baird PS-4 inductively
coupled plasma emission spectrometer (Baird Co., Bed-Sections of 2 to 3 mm thickness were cut using a Leitz
microtome (Leitz 1512; Leitz, Wetzlar, Germany). The ford, MA, USA). Serum cholesterol was determined us-
ing an enzymatic colorimetric method (CHOD-PAP, Hi-sections were deparaffinized and rehydrated prior to be-
ing stained with hematoxylin-eosin and Masson trichrome. tatchi 917; Roche Diagnostics, Mannheim, Germany).
The tissues were examined without knowledge of the
Statistical analysisrats’ identity. Interstitial, tubular, glomerular and vascu-
lar changes were quantitated using scores from 0 to 3 Statistical analysis was carried out by one-way analysis
of variance (ANOVA) followed by the Fisher’s pro-defined as:
Score 0. Normal arteriologlomerular unit with open tected least significant difference (PLSD) test. Data for
multiple observations over time were analyzed by two-capillary lumens and a normal afferent arteriole. No tubu-
lar atrophy, interstitial inflammation or interstitial fibro- way ANOVA with repeated measures for overall treat-
ment effect, and the Fisher’s test was used for multiplesis. Media slender in large vessels.
Score 1. Slight thickening of the media of the afferent pairwise comparisons of treatment groups at different
times. Differences between means of P , 0.05 werearteriole. Some mesangial thickening. Open capillary lu-
mens in the glomerulus. Patchy atrophy of tubular epi- considered significant. The data were analyzed using
SYSTAT statistical software (SYSTAT Inc., Evanston,thelium. Small interstitial fibrotic scars. Minimal medial
thickening in large vessels. IL, USA). The results are expressed as means 6 SEM.
Score 2. Marked mesangial thickening partly collapsed
capillaries in the glomerulus. Sometimes arteriolar thick-
RESULTS
ening. Diffuse tubular atrophy and striped fibrosis. Clear
Blood pressure, cardiac hypertrophy, and heart ratethickening of media in large vessels.
Score 3. Necrotic arterioglomerular units with media All CsA-treated SHRs receiving high-sodium diet, ir-
respective of dietary potassium and/or magnesium sup-necrosis of the arteriolar wall. Diffuse tubular atrophy
with many hyaline casts, striped fibrosis, sometimes me- plementations, were hypertensive at the end of the study
(Fig. 1). Dietary potassium supplementation decreaseddial necrosis of large vessels.
systolic blood pressure by 27 mm Hg at four weeks and
Hormonal, biochemical, and chemical determinations by 14 mm Hg at eight weeks in CsA-treated SHRs on
high-sodium diet. Magnesium supplementation, alone andPlasma renin activity was determined by a radioimmu-
noassay of angiotensin I (Medix Angiotensin I test; Medix, in combination with potassium, decreased blood pressure
as effectively as potassium supplementation. Left ventri-Biochemica, Kauniainen, Finland). Serum aldosterone
was determined by a solid-phase radioimmunoassay spe- cle wet weight was decreased only in SHRs receiving
the combination of potassium and magnesium (Fig. 2A).cific for aldosterone (Coat-A-Count Aldosterone; Diag-
nostic Products Corp., Los Angeles, CA, USA). Urinary When LVH was estimated as left ventricle wet weight-
to-body weight ratio, magnesium supplementation, alonenorepinephrine and dopamine were analyzed by high-
performance liquid chromatography (HPLC) with elec- and in combination with potassium, prevented the devel-
opment of LVH (Fig. 2B). Neither potassium nor magne-trochemical detection as described in detail elsewhere
[32]. Twenty-four–hour urine samples were collected sium supplementation markedly influences HR in CsA-
treated SHRs on a high-sodium diet (Fig. 3).into polypropylene tubes containing 1.0 mL 6 mol/L HCl
as the preservative and stored at 2808C until assayed. In WKY rats, CsA did not significantly increase blood
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Fig. 1. Line plots show development of hypertension in cyclosporine A
(CsA)-treated spontaneously hypertensive rats (SHRs) during different
diets for six weeks. Symbols are: (d) high-sodium diet; (s) high-sodium/
high-potassium diet; (h) high-sodium/high-magnesium diet; (j) high-
sodium/high-potassium/high-magnesium diet. Potassium and magnesium
Fig. 2. Left ventricle hypertrophy (LVH), expressed as left ventriclesupplementation, alone and in combination, decreased blood pressure
wet weight (A) and left ventricle wet weight-to-body weight ratio (B)in CsA-treated SHR on high-sodium diet. *P , 0.05 compared with
in CsA-treated SHR during different diets for six weeks. Magnesiumall other groups. Means 6 SEM are given, N 5 8 to 10 in each group.
supplementation, alone and in combination with potassium, ameliorated
LVH in CsA-treated SHRs on high-sodium diet. *P , 0.05 compared
with the high-sodium group; $P , 0.05 compared with the high-sodium/
high-magnesium group; §P , 0.05 compared with the high-sodium/
high-potassium group. Means 6 SEM are given, N 5 8 to 10 in each
group.pressure (Table 1). High-sodium diet alone increased
blood pressure moderately in WKY rats. CsA induced
a further increase in blood pressure in WKY rats on
high-sodium diet. High-sodium diet increased the abso-
affected (Fig. 4A). Magnesium supplementation, alonelute and relative heart weights, both in the presence and
and in combination with potassium, effectively preventedabsence of CsA treatment (Table 1).
the CsA-induced morphological changes in the kidneys,
whereas potassium supplementation only has a tendencyKidney morphology
to prevent CsA-induced renal damage (Fig. 4C).Cyclosporine A-treated SHRs on a high-sodium diet
The renal damage score in CsA-treated WKY ratsshowed severe thickening of the media of afferent arteri-
(0.21 6 0.08) and WKY rats receiving high-sodium dietole, fibrinoid necrosis of the arteriolar wall, hemorrhagic
(0.40 6 0.10) was not different from WKY controls (0.10 6necrosis of the glomerular tuft with some plump, and
0.06). However, CsA in combination with high-sodiumnon-necrotic mesangial cells. Some tubular swelling and
diet increased renal damage score by eightfold to nine-tubular dilation were observed close to the most affected
glomeruli. Approximately 80% of the glomeruli were fold (0.90 6 0.15; P , 0.05 compared with WKY controls).
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with magnesium supplemented treatment groups (Fig. 6).
Potassium supplementation had no effect on urinary do-
pamine excretion.
In WKY rats, neither CsA nor high-sodium diet sig-
nificantly influenced urinary dopamine excretion (dU-
dopamine 64 6 4, 77 6 6, and 54 6 5 nmol/day in WKY
controls, CsA-treated WKY rats, and in WKY rats on
high-sodium diet, respectively). Urinary dopamine ex-
cretion was lower in CsA-treated WKY on high-sodium
diet (51 6 9 nmol/day) compared with CsA-treated
WKY on low-sodium diet (P , 0.05).
Plasma-free magnesium concentration and bone
magnesium concentration
In CsA-treated SHRs on a high-sodium diet, plasma
iMg as well as bone magnesium concentrations were
lowest, although the differences did not quite reach sta-
tistical significance (Fig. 7). Magnesium supplementa-
tions were associated with 50 and 16% increases in
plasma iMg and bone Mg concentrations, respectively.
Potassium supplementation alone did not influence iMg
or bone magnesium concentrations.
In WKY rats, CsA decreased iMg by 23% compared
with WKY controls (Table 1). CsA decreased iMg also
during high-sodium diet, whereas a high-sodium diet
alone had no effect on iMg.
Hormonal, chemical, and biochemical determinations
Magnesium supplementation, alone and in combina-
tion with potassium, increased creatinine clearance, de-
creased serum creatinine and serum urea concentrations,
Fig. 3. Line plots show heart rates (HRs) in CsA-treated SHRs during and prevented the marked rise in PRA observed in CsA-different diets for six weeks. Abbreviations are given in Figure 1. CsA
treated SHR on high-sodium diet (Table 2). Potassiumincreased HR regardless of the diet. Means 6 SEM are given, N 5 8
to 10 in each group. supplementation alone tended to decrease serum urea
and PRA. There were no differences in plasma potas-
sium concentration or pH between different treatment
groups.Proteinuria and urinary NAG excretion
Serum cholesterol concentration in CsA-treated SHRs
During high-sodium intake, CsA induced a progres- on high-sodium diet, both in the presence and in the
sive increase in 24-hour urinary protein and NAG excre- absence of potassium supplementation, was higher com-
tions (Fig. 5). Potassium decreased proteinuria by 25%. pared with magnesium-supplemented and magnesium
Magnesium supplementation, alone and in combination plus potassium-supplemented SHRs (Fig. 8).
with potassium, decreased proteinuria by about 65%. In WKY rats, neither CsA nor high-sodium diet influ-
Neither potassium nor magnesium markedly affected enced serum cholesterol values (Table 1).
urinary NAG excretion in CsA-treated SHRs on high- Metabolic variables are given in Table 3. There were
sodium diet. no differences between the groups in food or water in-
In WKY rats, neither CsA nor high-sodium diet in- takes or in urine volume. Potassium and magnesium
creased proteinuria (ANOVA, P 5 0.35). supplementations caused marked increases in urinary
excretions of corresponding electrolytes. Interestingly,
Urinary catecholamine excretion magnesium supplementation markedly increased urinary
There were no differences in the 24-hour urinary nor- calcium excretion.
epinephrine excretion between the different treatment
Whole blood, kidney, and heart CsA concentrationsgroups (ANOVA, P 5 0.74, data not shown). Urinary
dopamine excretion was approximately 50% lower in Cyclosporine A concentrations in whole blood, kid-
ney, and heart averaged 730 6 52 ng/mL, 127 6 6 ng/g,CsA-treated SHRs on a high-sodium diet as compared
Pere et al: K and Mg in CsA toxicity 2467
Table 1. Cardiovascular effects of 8 weeks of cyclosporine A (CsA) treatment and a high-sodium diet (NaCl) in normotensive
Wistar-Kyoto (WKY) rats
Controls CsA NaCl NaCl 1 CsA ANOVA
Systolic blood pressure mm Hg 13064 13461 14663ab 15764abc ,0.001
Body weight g 461621 407612 438623 407620 0.17
Left ventricle weight g 0.93360.041 0.76260.029a 0.99160.033b 0.92760.057b 0.01
LVH mg/g 2.0360.03 1.9060.03 2.2760.06ab 2.2860.08ab ,0.001
iMg mmol/L 0.5260.009 0.4060.01ac 0.4860.016 0.3860.017ac ,0.001
pH 7.4160.02 7.3360.03 7.3660.06 7.4560.01 0.08
Serum cholesterol mmol/L 1.9060.15 2.0060.14 1.9860.15 2.1560.10 0.59
Data are means 6 SEM. N 5 5 to 6 in each group. Abbreviations are: LVH, left ventricular hypertrophy; iMg, plasma-free magnesium.
a P , 0.05 vs. WKY controls
b P , 0.05 vs. CsA group
c P , 0.05 vs. NaCl group
Fig. 4. Representative photomicrographs from the kidneys of CsA-
treated SHR on high-sodium diet (A) and normotensive WKY rat (B).
CsA-treated SHR on high-sodium diet showed severe thickening of the
media of afferent arteriole and fibrinoid necrosis of the arteriolar wall.
Potassium only partially prevented CsA-induced renal damage. Magne-
sium supplementation, alone and in combination, prevented the CsA-
induced morphological changes in the kidney (C). *P , 0.05 compared
with the high-sodium group; §P , 0.05 compared with the high-sodium/
high-potassium group. Means 6 SEM are given, N 5 8 to 10 in each
group.
and 71 6 4 ng/g, respectively. Modifications of dietary and nephrotoxicity [26, 27]. There is accumulating evi-
dence to suggest that high-sodium intake aggravates CsAelectrolyte composition did not influence whole blood,
toxicity. Using NaCl-loaded SHRs as an experimentalkidney, or heart CsA concentrations.
model, we tested the hypothesis of whether concurrent
oral supplementation with potassium and magnesium
DISCUSSION could ameliorate CsA-induced hypertension and neph-
The use of immunosuppressive agent CsA is often rotoxicity more effectively than supplementation with
one mineral alone. We confirmed our recent finding thatlimited by drug-induced side effects like hypertension
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Fig. 6. Twenty-four–hour urinary dopamine excretion in CsA-treated
SHR during different diets for six weeks. Magnesium supplementation,
alone and in combination with potassium, prevented the suppression
of urinary dopamine excretion in CsA-treated SHRs on high-sodium
diet. *P , 0.05 compared with the high-sodium diet group; §P , 0.05
compared with the high-sodium/high-potassium diet group. Means 6
SEM are given, N 5 8 to 10 in each group.
effect of magnesium clearly exceeded that of potassium.
The greatest protection against CsA-induced hyperten-
sion and nephrotoxicity was achieved when potassium
and magnesium were combined.
Hypertension is a major risk factor for renal failure.
It has been shown previously that hypertension typically
induces endothelial injury and severe intimal thickening
in interlobular arteries [35]. The morphological changes
Fig. 5. Line plots show the development of proteinuria (A) and urinary found in the kidneys of CsA-treated SHR on high-sodiumNAG excretion (B) in CsA-treated SHRs during different diets for
diet closely resembled those observed in malignant hy-six weeks. Symbols are: (d) high-sodium diet; (s) high-sodium/high-
potassium diet; (h) high-sodium/high-magnesium diet; (j) high-sodium/ pertension and support the notion that arterial hyperten-
high-potassium/high-magnesium diet. Potassium partially prevented the sion plays a central role in the pathogenesis of kidneydevelopment of proteinuria, whereas magnesium supplementation,
alone and in combination, was more effective. CsA increased urinary damage in our animal model. In the present study, we
NAG excretion irrespective of the diet. *P , 0.05 vs. all other groups, found that magnesium, alone and in combination with
§P , 0.05 vs. high-magnesium and high-magnesium/high-potassium diet
potassium, protects against CsA-induced mesangial thick-groups. Means 6 SEM are given, N 5 8 to 10 in each group.
ening, medianecrosis of the arteriolar wall, diffuse tubu-
lar atrophy, and striped fibrosis. Our findings are thus
in very good accordance with the previous findings by
high-sodium diet induces severe hypertension and deteri- Mathew et al demonstrating that oral magnesium supple-
orates renal functions in CsA-treated SHRs. We also mentation attenuates vascular damage in experimentally
provided here evidence that the development of CsA- induced pulmonary hypertension [36].
induced glomerular, tubular, and vascular lesions are There is also accumulating evidence to suggest that
associated with renal dopaminergic deficiency. Both po- potassium deficiency plays a role in the pathogenesis of
tassium and magnesium supplementation showed bene- arterial hypertension and hypertension-related kidney
damage [1, 8]. Potassium supplementation attenuates so-ficial effects against CsA toxicity; however, the protective
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mentation. Therefore, it is likely that the protection
against the development of proteinuria and renal func-
tional disturbances by potassium supplementation is me-
diated, at least in part, by blood pressure-independent
mechanisms. Hence, our study supports previous findings
by Tobian et al [8, 9]. The antihypertensive and renopro-
tective effects of potassium supplementation were still
minor when compared with those produced by magne-
sium [29] or angiotensin-converting enzyme inhibitor
[30]. It is also noteworthy that potassium supplementa-
tion did not produce any signs of hyperkalemia during
six-week experimental period in CsA-treated SHRs on
high-sodium diet.
Experimental and epidemiological studies have linked
hypertension, hypertensive heart disease, and ischemic
heart disease with soft water containing a small amount
of magnesium [5, 39, 40]. Magnesium deficiency has been
shown to deteriorate hypokalemia, cause cardiac ar-
rhythmias, and expose digitalis-induced side effects [5,
40, 41]. Furthermore, magnesium deficiency induces se-
vere vascular damage in the heart and kidney, accelerates
the development of atherosclerosis, causes vasoconstric-
tion of the coronary arteries [13, 42], increases blood
pressure, and induces thrombocyte aggregation [41].
Magnesium infusions, even when given at physiological
concentrations, produce vasodilation of systemic vascu-
lature and coronary arteries [13–16]. Magnesium infu-
sion also produces platelet inhibition and anti-arrhyth-
mic effects [5, 16]. Previous studies have shown that
cardiac damage induced by magnesium deficiency is as-
sociated with the generation of reactive oxygen species
[43] and that magnesium effectively protects myocar-
dium against ischemia-reperfusion injury in experimen-
tal animals, especially when administered before reper-Fig. 7. Serum-free magnesium concentration (iMg; A) and bone mag-
fusion occurs [5, 16]. In accordance with our previousnesium concentration (B), in CsA-treated SHR during different diets for
six weeks. Magnesium supplementation, alone and in combination with findings, oral magnesium supplementation effectively
potassium, increased iMg and bone magnesium concentrations in CsA- corrected magnesium deficiency and ameliorated CsA-treated SHR on high-sodium diet. *P , 0.05 compared with high-
induced hypertension and nephrotoxicity [29, 30]. Thesodium/high-potassium diet groups. Means 6 SEM are given, N 5 8
to 10 in each group. beneficial effects of the combination of potassium and
magnesium supplementations tended to be greater than
those of magnesium supplementation alone. The normal
iMg values in WKY rats reported here are in consistent
dium-induced elevation of blood pressure in patients and with previous studies by Altura et al [44, 45].
animals with salt-sensitive hypertension, but does not Dopamine plays an important role in the regulation
affect the blood pressure in the sodium-depleted state of renal sodium excretion. The synthesis of dopamine
[8, 11, 37, 38]. This suggests that the antihypertensive and the presence of several dopamine receptor subtypes
action of potassium might be related to the natriuresis have been shown in the kidney [reviewed in 46]. Stimula-
leading to a decrease in the volume load [10, 37, 38]. tion of D1-receptors in the kidney causes an increase in
However, potassium seems to protect against renal dam- renal blood flow, glomerular filtration rate, as well as an
age and reduce cerebral hemorrhage even by a blood increase in urinary excretion of sodium and water [46].
pressure-independent mechanism as Tobian demon- Dopamine increases renal sodium excretion through in-
strated [8]. In the present study, potassium supplementa- hibition of sodium-transporting proteins (Na,K-ATPase,
tion clearly decreased blood pressure after a four-week Na, H-exchanger) [46]. It has been demonstrated that
follow-up period, whereas the antihypertensive action high-sodium diet increases urinary dopamine excretion
[47, 48]. There is now accumulating evidence to suggestwas less prominent after eight weeks of dietary supple-
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Table 2. Factors affecting renal functions of CsA-treated spontaneously hypertensive rats on different diets for six weeks
NaCl NaCl 1 K NaCl 1 Mg NaCl 1 K 1 Mg ANOVA
Serum creatinine mmol/L 7763 7067 5565ab 5263ab ,0.001
Creatinine clearance mL/min 0.760.04 0.760.1 1.160.08ab 1.160.06ab 0.002
Serum urea mmol/L 16.161.8 12.462.9 7.961.5a 6.660.4ab 0.001
PRA ng Ang I mL/hour 47.765.6 31.4610.7 21.267.6a 7.062.5ab 0.003
Serum aldosterone nmol/L 7356105 12186342 5146165b 3276144b 0.03
Plasma potassium mmol/L 6.460.2 6.660.3 6.660.2 6.460.1 0.72
pH 7.7860.03 7.7260.02 7.6260.04 7.6260.07 0.07
Data are means 6 SEM. N 5 10 in each group. Abbreviations are: plasma renin activity. NaCl, high-sodium diet; K, high-potassium diet; Mg, high-magnesium
diet; PRA, plasma renin activity.
a P , 0.05 vs. NaCl group
b P , 0.05 vs. NaCl 1 K group
when given concurrently with high-sodium diet. To our
knowledge, the present study provides first evidence that
the renoprotective effect of magnesium, alone and in
combination with potassium, is associated with preven-
tion of CsA-induced renal dopaminergic deficiency. Our
findings also suggest that D1 receptor agonists might
provide therapeutic potential in the treatment of CsA-
induced hypertension.
Hypercholesterolemia, which occurs frequently in re-
nal transplant recipients, contributes to the high cardio-
vascular morbidity and mortality in these patients. Mag-
nesium deficiency has been associated with hypertension,
abnormal glucose and lipid metabolism, and accelerated
atherosclerosis [50]. Markell et al have previously shown
that low plasma-ionized magnesium concentration asso-
ciates with hypertension, nephrotoxicity, and hypercho-
lesterolemia in CsA-treated renal transplant recipients [31].
Cyclosporine increases the oxidizability of low-density li-
poproteins in renal transplant recipients [51], and a recent
prospective study by Holvoet et al revealed that oxidized
low-density lipoprotein is a prognostic marker of trans-Fig. 8. Serum cholesterol concentration in CsA-treated SHRs during
different diets for six weeks. Serum cholesterol concentration in CsA- plant-associated coronary artery disease [52]. Taken to-
treated SHR on high-sodium diet, both in the presence and in the gether, these studies strongly suggest that changes in
absence of potassium supplementation, was higher compared with mag-
lipid metabolism are also involved in the pathogenesisnesium-supplemented and magnesium 1 potassium-supplemented SHRs.
*P , 0.05 compared with the high-sodium diet group; §P , 0.05 com- of CsA-induced vascular damage. In line with the pre-
pared with the high-sodium/high-potassium diet group. Means 6 SEM viously mentioned findings, we found in the present studyare given, N 5 8 to 10 in each group.
that the beneficial and protective effects of magnesium
supplementation were associated with a decrease in se-
rum cholesterol concentration. Magnesium repletion also
that renal dopamine production and/or dopamine recep- has been shown to improve lipid metabolism in hypo-
tor function are defective in human primary hyperten- magnesemic renal transplant recipients [53]. However,
sion as well as in genetic animal models of hypertension it should be pointed out that the use of serum total
[46, 49]. The important finding of the present study was cholesterol measurement only gives a crude estimate of
that, in SHRs on high-sodium diet, CsA-induced hyper- changes in lipid metabolism, and since the serum choles-
tension and nephrotoxicity is associated with a renal terol level in normotensive WKY rats is higher compared
dopaminergic deficiency. In accordance with the previ- with SHRs [54, 55], serum cholesterol measurements
ous findings [47, 48], we found in our pilot study that might have only limited value in experimental studies
high-sodium diet alone increases urinary dopamine ex- carried out in hypertensive rats.
cretion in SHRs by approximately 50% (Mervaala, un- Urinary protein excretion is commonly used as a marker
published data). Interestingly, even in normotensive of glomerular damage, whereas urinary NAG excretion
serves as an indicator of proximal tubular damage [56].WKY rats, CsA decreased urinary dopamine excretion
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Table 3. Body and kidney weights, 24-hour food and water intakes, urine volume and urinary excretion rates of various mineral elements
of CsA-treated spontaneously hypertensive rats after six weeks on different diets
NaCl NaCl 1 K NaCl 1 Mg NaCl 1 K 1 Mg ANOVA
Body weight g 22366 21466 25568a,b 24065b ,0.001
Left 1 right kidney weight g 1.860.02 1.760.03a 1.760.03a 1.760.02a ,0.001
Kidney weight/body weight mg/g 8.160.2 8.160.3 6.860.2a,b 6.860.2a,b ,0.001
Food intake g/day 20.061.2 19.361.3 20.560.7 20.560.9 0.45
Water intake mL/day 109.5612.6 113.365.5 119.3619.3 106.963.8 0.81
Urine volume mL/day 102.8610.7 101.564.9 78.267.3 87.264.7 0.26
Sodium mmol/day 16.161.8 12.661.2a 17.860.9b 16.360.7b 0.01
Potassium mmol/day 2.260.1 6.360.5 2.460.1 8.660.3a,b,c ,0.001
Magnesium mmol/day 213620 189618 772647a,b 761640a,b ,0.001
Calcium mmol/day 241649 230619 414629a,b 436639a,b ,0.001
Phosphorus mmol/day 0.660.05 0.760.03 0.560.7a,b 0.460.04a,b ,0.001
Data are means 6 SEM, N 5 10 in each group. Abbreviations are explained in the legend of Table 2.
a P , 0.05 vs. NaCl group
b P , 0.05 vs. NaCl 1 K group
c P , 0.05 vs. NaCl 1 Mg group
NAG is a hydrolytic enzyme that acts on glycosyl com- REFERENCES
pounds and is widely distributed in various tissues [56]. 1. Svetkey L, Klotman P: Blood pressure and potassium intake,
in Hypertension: Pathophysiology, Diagnosis, and Management,In the kidney, NAG is mainly located in the lysosomal
edited by Laragh JH, Brenner BM, New York, Raven Press,fraction and to a lesser extent in the microsomal fraction
1990, pp 217–227
of the tubular cells [56]. In our pilot study, CsA increased 2. Dyer A, Elliot P, Shipley M: Urinary electrolyte excretion in 24
hours and blood pressure in the INTERSALT study. II. Estimatesurinary NAG excretion in SHRs on a low-sodium diet
of electrolyte-blood pressure associations corrected for regressionby approximately 50% without changing urinary protein
dilution bias. Am J Epidemiol 139:940–951, 1994
excretion, indicating that CsA induces minor proximal 3. Dyer A, Shipley M, Elliot P: Urinary electrolyte excretion in 24
hours and blood pressure in the INTERSALT study. I. Estimatestubular damage even during low sodium diet, and that
reliability. Am J Epidemiol 139:927–939, 1994proximal tubular damage precedes the development of
4. Arsenian M: Magnesium and cardiovascular disease. Prog Cardio-
drug-induced glomerular and vascular lesions. Our find- vasc Dis 35:271–310, 1993
5. Altura BM, Altura BT: Role of magnesium in the pathogenesisings also suggest that a urinary NAG measurement might
of hypertension updated: Relationship to its action on cardiac,be useful when estimating the early signs of CsA nephro-
vascular smooth muscle, and endothelial cells, in Hypertension:
toxicity in humans. Interestingly, dietary supplementa- Pathophysiology, Diagnosis, and Management (2nd ed), edited by
Laragh J, Brenner BM, New York, Raven Press, 1995, pp 1213–tion with magnesium and/or potassium had no effect
1242on the development of CsA-induced proximal tubular
6. Teo K, Yusuf S: Role of magnesium in reducing mortality in acutedamage. myocardial infarction: A review of the evidence. Drugs 46:347–359,
In conclusion, our findings indicate that both potas- 1993
7. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Foll-sium and magnesium supplementation show beneficial
mann D, Klag MJ: Effects of oral potassium on blood pressure:effects against CsA-induced hypertension and nephro- Meta-analysis of randomized controlled clinical trials. JAMA
toxicity; however, the protective effect of magnesium 277:1624–1632, 1997
8. Tobian L: Potassium and sodium in hypertension: The Volhardclearly exceeds that of potassium. The greatest protec-
Lecture. J Hypertens 6(Suppl 4):12–24, 1988tion against CsA toxicity is achieved when potassium 9. Tobian L, Lange J, Ulm K, Wold L, Iwai J: Potassium reduces
and magnesium are combined. We also provide evidence cerebral hemorrhage and death rate in hypertensive rats, even
when blood pressure in not lowered. Hypertension 7:I110–I114,that the development of CsA-induced glomerular, tubu-
1985lar, and vascular lesions are associated with renal dopa- 10. Young D, McCaa R, Pan Y-J, Guyton A: The natriuretic and
minergic deficiency. hypotensive effects of potassium. Circ Res 38:84–89, 1976
11. Fujita T, Noda H, Ando K: Sodium susceptibility and potassium
effects in young patients with borderline hypertension. CirculationACKNOWLEDGMENTS
69:468–476, 1984
12. Young D, Lin H, McCabe R: Potassium’s cardiovascular protec-The study was supported by the Helsinki University Central Hospi-
tive mechanisms. Am J Physiol 268:R825–R837, 1995tal Funds, the Academy of Finland, the Finnish Foundation of Cardio-
13. Turlapaty PD, Altura BM: Magnesium deficiency producesvascular Research, and the Sigrid Juse´lius Foundation. We thank Ms.
spasms of coronary arteries: Relationship to etiology of suddenNada Bechara-Hirvonen, Ms. Remi Hakama, Ms. Toini Siiskonen Ms.
death ischemic heart disease. Science 208:198–200, 1980Marja-Liisa Ra¨sa¨nen, Ms. Saara Merasto, and Mr. Stephen Venn for
14. Nagai I, Gebrewold A, Altura BT, Altura BM: Magnesiumproviding excellent technical assistance.
salts exert direct vasodilator effects on rat cremaster muscle micro-
circulation. Arch Int Pharmacodyn Ther 294:194–214, 1988Reprint requests to Eero Mervaala, M.D., Ph.D., Institute of Biomedi-
15. Nishio A, Gebrewold A, Altura BT, Altura BM: Comparativecine, Department of Pharmacology and Toxicology, P.O. Box 8, FIN-
vasodilator effects of magnesium salts on rat mesenteric arterioles00014 University of Helsinki, Helsinki, Finland.
E-mail: eero.mervaala@helsinki.fi and venules. Arch Int Pharmacodyn Ther 298:139–163, 1989
Pere et al: K and Mg in CsA toxicity2472
16. Woods KL: Possible pharmacological actions of magnesium in 35. Tobian L: Hypothesis: Low dietary K may lead to renal failure in
blacks with hypertension and severe intimal thickening. Am J Medacute myocardial infarction. Br J Clin Pharmacol 32:3–10, 1991
17. Whelton P, Klag M: Magnesium and blood pressure: Review of Sci 295:384–388, 1988
36. Mathew R, Gloster ES, Altura BT, Altura BM: Magnesiumthe epidemiological and clinical trial experience. Am J Cardiol
63:26G–30G, 1989 aspartate hydrochloride attenuates monocrotaline-induced pulmo-
nary artery hypertension in rats. Clin Sci (Colch) 75:661–667, 198818. Altura BM, Altura BT, Carella A, Turlapaty PD: Ca21 cou-
pling in vascular smooth muscle: Mg21 and buffer effects on con- 37. Fujita T, Ando K: Hemodynamic and endocrine changes associ-
ated with potassium supplementation in sodium-loaded hyperten-tractility and membrane Ca21 movements. Can J Physiol Pharma-
col 60:459–482, 1982 sives. Hypertension 6:184–192, 1984
38. Linas S: The role of potassium in the pathogenesis and treatment19. Iseri LT, French JH: Magnesium: Nature’s physiologic calcium
blocker. Am Heart J 108:188–193, 1984 of hypertension. Kidney Int 39:771–786, 1991
39. Marx A, Neutra RR: Magnesium in drinking water and ischaemic20. Karppanen H: New oral salt in treatment of high blood pressure.
Magnesium 8:274–287, 1989 heart disease. Epidemiol Rev 19:258–272, 1997
40. Karppanen H: Epidemiologic evidence for considering magnesium21. Mervaala EMA, Himberg J-J, Laakso J, Tuomainen P, Karppa-
nen H: Beneficial effects of a potassium- and magnesium-enriched deficiency as a risk factor for cardiovascular diseases. Magnes Bull
12:80–86, 1990salt alternative. Hypertension 19:535–540, 1992
22. Mervaala EMA, Paakkari I, Laakso J, Nevala R, Tera¨va¨inen 41. Seelig M: Magnesium Deficiency in the Pathogenesis of Disease:
Early Roots of Cardiovascular, Skeletal, and Renal Abnormalities.T, Fyhrquist F, Vapaatalo H, Karppanen H: Replacement of
salt by a novel potassium- and magnesium-enriched salt alternative New York, Plenum Medical Book Co., 1980
42. Altura BM: Sudden-death ischemic heart disease and dietaryimproves the cardiovascular effects of ramipril. Br J Pharmacol
111:1189–1197, 1994 magnesium intake: Is the target site coronary vascular smooth
muscle? Med Hypotheses 5:843–848, 197923. Mervaala EMA, Laakso J, Vapaatalo H, Karppanen H: Im-
provement of cardiovascular effects of metoprolol by replacement 43. Wu F, Altura BT, Gao J, Barbour RL, Altura BM: Ferrylmyo-
globin formation induced by acute magnesium deficiency in per-of common salt with a potassium- and magnesium-enriched salt
alternative. Br J Pharmacol 112:640–648, 1994 fused rat heart causes cardiac failure. Biochim Biophys Acta
1225:158–164, 199424. Mervaala EMA, Malmberg L, Tera¨va¨inen T-L, La¨hteenma¨ki
T, Karjala K, Vapaatalo H, Karppanen H: Influence of dietary 44. Altura BM, Altura BT, Gupta RK: Alcohol intoxication results
in rapid loss in free magnesium in brain and disturbances in brainsalt on the cardiovascular and renal effects of moxonidine in spon-
taneously hypertensive rats. Naunyn Schmiedeberg Arch Pharma- bioenergetics: Relation to cerebrovasospasm, alcohol-induced
strokes, and barbiturate anesthesia-induced deaths. Magnes Tracecol 356:107–114, 1997
25. Mervaala EMA, Malmberg L, Tera¨va¨inen T-L, Laakso J, Va- Elem 10:122–135, 1991–1992
45. Altura BM, Gebrewold A, Altura BT, Gupta RK: Role ofpaatalo H, Karppanen H: Influence of dietary salts on the cardio-
vascular effects of low-dose combination of ramipril and felodipine brain [Mg21]i in alcohol-induced hemorrhagic stroke in a rat model:
A 31P-NMR in vivo study. Alcohol 12:131–136, 1995in spontaneously hypertensive rats. Br J Pharmacol 123:195–204,
1998 46. Hussain T, Lokhandwala MF: Renal dopamine receptor function
in hypertension. Hypertension 32:187–197, 199826. Faulds D, Goa KL, Benfield P: Cyclosporin. A review of its
pharmacodynamic and pharmacokinetic properties, and therapeu- 47. Vyass SJ, Jadlav AL, Eichberg J, Lokhandwala MF: Dopamine
receptor-mediated activation of phospholipase C is associated withtic use in immunoregulatory disorders. Drugs 45:953–1040, 1993
27. van Gelder T, Balk AH, Zietse R, Hesse C, Mochtar B, Weimar natriuresis during high salt intake. Am J Physiol 262:F494–F498,
1992W: Renal insufficiency after heart transplantation: A case-control
study. Nephrol Dial Transplant 13:2322–2326, 1998 48. Bertorello A, Hokfelt T, Goldstein M, Aperia A: Proximal
tubule Na,K-ATPase activity is inhibited during high salt diet:28. Curtis JJ, Luke RG, Jones P, Diethelm AG: Hypertension in
cyclosporine-treated renal transplant recipients is sodium depen- Evidence for DA-mediated effect. Am J Physiol 254:F795–F801,
1988dent. Am J Med 85:134–138, 1988
29. Mervaala EMA, Pere A-K, Lindgren L, Laakso J, Tera¨va¨inen 49. Pestana M, Jardim H, Serrao P, Soares-da-Silta P, Guerra L:
Reduced urinary excretion of dopamine and metabolites in chronicT-L, Karjala K, Vapaatalo H, Ahonen J, Karppanen H: Effects
of dietary sodium and magnesium on cyclosporine A-induced hy- renal parenchymal disease. Kidney Blood Press 21:59–65, 1998
50. Saris NL, Mervaala E, Karppanen H, Khawaja JA, Lewenstampertension and nephrotoxicity in spontaneously hypertensive rats.
Hypertension 29:822–827, 1997 A: Magnesium: An update on physiological, clinical and analytical
aspects. Clin Chim Acta 294:1–26, 199930. Mervaala EMA, Lassila M, Vaskonen T, Krogerus L, La¨hteen-
ma¨ki T, Vapaatalo H, Karppanen H: Effects of ACE inhibition 51. Apanay DC, Neylan JF, Ragab MS, Sgoutas DS: Cyclosporine
increases the oxidizability of low-density lipoproteins in renalof cyclosporine A-induced hypertension and nephrotoxicity in
spontaneously hypertensive rats on high sodium diet. Blood Press transplant recipients. Transplantation 58:663–669, 1994
52. Holvoet P, Van Cleemput J, Collen D, Vanhaecke J: Oxidized8:49–56, 1999
31. Markell MS, Altura BT, Barbour RL, Altura BM: Ionized low density lipoprotein is a prognostic marker of transplant-associ-
ated coronary artery disease. Arterioscler Thromb Vasc Bioland total magnesium levels in cyclosporin-treated renal transplant
recipients: Relationship with cholesterol and cyclosporin levels. 20:698–702, 2000
53. Gupta BK, Glicklich D, Tellis VA: Magnesium repletion ther-Clin Sci (Colch) 85:315–318, 1993
32. Tuomainen P, Mannisto¨ P: Optimization of the hydrolysis of con- apy improved lipid metabolism in hypomagnesemic renal trans-
plant recipients: A pilot study. Transplantation 67:1485–1487, 1999jugated L-DOPA, dopamine and dihydroxyphenylacetic acid in
human urine for assay by high-performance liquid chromatography 54. Sawamura M, Nara Y, Yamori Y: Liver mevalonate 5-pyrophos-
phate decarboxylase is responsible for reduced serum cholesterolwith electrochemical detection. Eur J Clin Chem Clin Biochem
35:229–235, 1997 in stroke-prone spontaneously hypertensive rat. J Biol Chem
267:6051–6055, 199233. Noto A, Ogawa Y, Mori S, Yoshioka M, Kitakaze T, Hori
T, Nakamura M, Miyake T: Simple rapid spectrophotometry of 55. Iritani N, Fukuda E, Yamori Y: Lipid metabolism in spontane-
ously hypertensive rats (SHR). Atherosclerosis 28:217–222, 1977urinary N-acetyl-b-d-glucosaminidase with use of new chromo-
genic substrate. Clin Chem 29:1713–1716, 1983 56. Sherman RL, Drayer DE, Leyland-Jones BR, Reidenberg MM:
N-acetyl-13-glucosaminidase and beta-2-microglobulin: Their uri-34. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein
measurement with the folin phenol reagent. J Biol Chem 193:265– nary excretion in patients with renal parenchymal disease. Arch
Intern Med 143:1183–1185, 1983275, 1951
